Leptin deficiency: clinical implications and opportunities for therapeutic interventions.
The discovery of leptin has significantly advanced our understanding of the metabolic importance of adipose tissue and has revealed that both leptin deficiency and leptin excess are associated with severe metabolic, endocrine, and immunological consequences. We and others have shown that a prominent role of leptin in humans is to mediate the neuroendocrine adaptation to energy deprivation. Humans with genetic mutations in the leptin and leptin receptor genes have deregulated food intake and energy expenditure leading to a morbidly obese phenotype and a disrupted regulation in neuroendocrine and immune function and in glucose and fat metabolism. Observational and interventional studies in humans with (complete) congenital leptin deficiency caused by mutations in the leptin gene or with relative leptin deficiency as seen in states of negative energy balance such as lipoatrophy, anorexia nervosa, or exercise-induced hypothalamic and neuroendocrine dysfunction have contributed to the elucidation of the pathophysiological role of leptin in these conditions and of the clinical significance of leptin administration in these subjects. More specifically, interventional studies have demonstrated that several neuroendocrine, metabolic, or immune disturbances in these states could be restored by leptin administration. Leptin replacement therapy is currently available through a compassionate use program for congenital complete leptin deficiency and under an expanded access program to subjects with leptin deficiency associated with congenital or acquired lipoatrophy. In addition, leptin remains a potentially forthcoming treatment for several other states of energy deprivation including anorexia nervosa or milder forms of hypothalamic amenorrhea pending appropriate clinical trials.
Blüher
Susan
S
Hospital for Children and Adolescents, University of Leipzig, Germany.
Shah
Sunali
S
Mantzoros
Christos S
CS
D000311:Adrenal Glands / Q000502:physiology; D000568:Amenorrhea / Q000503:physiopathology; D000856:Anorexia Nervosa / Q000503:physiopathology; D003071:Cognition / Q000502:physiology; D005260:Female; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D020738:Leptin / Q000172:deficiency* / Q000502:physiology / Q000627:therapeutic use; D008060:Lipodystrophy / Q000503:physiopathology; D008297:Male; D008954:Models, Biological; D009490:Neurosecretory Systems / Q000502:physiology; D012098:Reproduction / Q000502:physiology; D013961:Thyroid Gland / Q000502:physiology
D020738:Leptin